DOI QR코드

DOI QR Code

Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer

  • Okutur, Kerem (Department of Medical Oncology, Acibadem University School of Medicine) ;
  • Bassulu, Nuray (Department of Pathology, Istanbul Bilim University School of Medicine) ;
  • Dalar, Levent (Department of Chest Disease, Istanbul Bilim University School of Medicine) ;
  • Aydin, Kubra (Ankara Oncology Training and Research Hospital) ;
  • Bozkurt, Mustafa (Department of Medical Oncology, Acibadem University School of Medicine) ;
  • Pilanci, Kezban Nur (Istanbul Bilim University School of Medicine) ;
  • Dogusoy, Gulen Bulbul (Department of Pathology, Istanbul Bilim University School of Medicine) ;
  • Tecimer, Coskun (Istanbul Bilim University School of Medicine) ;
  • Mandel, Nil Molinas (Department of Medical Oncology, Koc University School of Medicine) ;
  • Demir, Gokhan (Department of Medical Oncology, Acibadem University School of Medicine)
  • Published : 2015.04.14

Abstract

Background: The phosphatidylinositol 3'-kinase/Akt (PI3K/Akt) pathway is a key regulator for HER2-overexpressing breast cancer, but data about whether activation of PI3K/Akt is associated with poor prognosis and resistance to trastuzumab therapy is controversial. In this study we investigated predictive and prognostic significance of expression of p27, Akt, PTEN and PI3K, which are components of the PI3K/Akt signaling pathway, in HER2-positive metastatic breast cancer (MBC), retrospectively. Materials and Methods: Fifty-four HER2-positive MBC patients who had received first-line trastuzumab-based therapy were recruited for the study group. All of the patient's breast tissue samples were examined for p27 and Akt expression. In addition, twenty-five patients with sufficient amount of tumor tissue were also examined for PTEN and PI3K expression. p27, Akt, PTEN and PI3K were evaluated by immunohistochemistry and their relationship with patient demographic features, tumor characteristics, response to trastuzumab-based treatment and survival outcomes were analyzed. Results: p27, Akt, PTEN and PI3K were positive in 25.9%, 70.4%, 24% and 96% of the cases, respectively. Nomne were significantly associated with response to trastuzumab and time to progression (TTP). A trend toward statistical significance for longer overall survival (OS) was found for PTEN-positive patients (p=0.058); there was no significant relationship between the other immunohistochemical variables and OS. When we analyzed groups regarding co-expression, the PTEN-negative/Akt-negative group had a significantly lower objective response rate (ORR) (20% vs 80%, p=0.023) and the PTEN-negative/p27-negative and PTEN-negative/Akt-negative groups had significantly lower median OS compared to other patients (26.4 months vs 76.1 months, p=0.005 and 25.6 months vs 52.0 months, p=0.007, respectively). Conclusions: p27, Akt, PTEN and PI3K expression is not statistically significantly associated with ORR, TTP and OS, individually. However, the combined evaluation of p27, Akt and PTEN could be helpful to predict the response to trastuzumab-based therapy and prognosis in HER2-positive MBC.

Keywords

Breast cancer;HER2, p27;Akt;PTEN;trastuzumab;response to therapy

References

  1. Berns K, Horlings HM, Hennessy BT, et al (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 12, 395-402. https://doi.org/10.1016/j.ccr.2007.08.030
  2. Chen W, Yang H, Tang WR, Feng SJ, Wei YL (2014). Updated meta-analysis on HER2 polymorphisms and risk of breast cancer: evidence from 32 studies. Asian Pac J Cancer Prev, 15, 9643-7. https://doi.org/10.7314/APJCP.2014.15.22.9643
  3. Dave B, Migliaccio I, Gutierrez MC, et al (2011). Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol, 29, 166-73. https://doi.org/10.1200/JCO.2009.27.7814
  4. Depowski PL, Rosenthal SI, Ross JS (2001). Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol, 14, 672-6. https://doi.org/10.1038/modpathol.3880371
  5. Di Leo A, Gancberg D, Larsimont D, et al (2002). HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res, 8, 1107-16.
  6. Engin H, Baltali E, Guler N, et al (2006). Expression of PTEN, cyclin D1, P27/KIP1 in invasive ductal carcinomas of the breast and correlation with clinicopathological parameters. Bull Cancer, 93, 21-6.
  7. Esteva FJ, Guo H, Zhang S, et al (2010). PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol, 177, 1647-56. https://doi.org/10.2353/ajpath.2010.090885
  8. Fabi A, Metro G, Di Benedetto A, et al (2010). Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology, 78, 141-9. https://doi.org/10.1159/000312656
  9. Fiszman GL, Jasnis MA (2011). Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer, 2011, 352182.
  10. Gori S, Sidoni A, Colozza M, et al (2009). EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol, 20, 648-54. https://doi.org/10.1093/annonc/mdn681
  11. Hayes DF, Thor AD, Dressler LG, et al (2007). HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med, 357, 1496-506. https://doi.org/10.1056/NEJMoa071167
  12. Jonason JH, Gavrilova N, Wu M, Zhang H, Sun H (2007). Regulation of SCF(SKP2) ubiquitin E3 ligase assembly and p27(KIP1) proteolysis by the PTEN pathway and cyclin D1. Cell Cycle, 6, 951-61. https://doi.org/10.4161/cc.6.8.4104
  13. Li SY, Rong M, Grieu F, Iacopetta B (2006). PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat, 96, 91-5. https://doi.org/10.1007/s10549-005-9048-0
  14. Liu P, Cheng H, Roberts TM, Zhao JJ (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 8, 627-44. https://doi.org/10.1038/nrd2926
  15. Liu AN, Sun P, Liu JN, et al (2012). Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev, 13, 1197-201. https://doi.org/10.7314/APJCP.2012.13.4.1197
  16. Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23, 4265-74. https://doi.org/10.1200/JCO.2005.04.173
  17. Nagata Y, Lan KH, Zhou X, et al (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-27. https://doi.org/10.1016/j.ccr.2004.06.022
  18. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ (2004). P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res, 64, 3981-6. https://doi.org/10.1158/0008-5472.CAN-03-3900
  19. Nahta R, Esteva FJ (2006). HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res, 8, 215. https://doi.org/10.1186/bcr1612
  20. Newman L, Xia W, Yang HY, et al (2001). Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog, 30, 169-75. https://doi.org/10.1002/mc.1025
  21. Perez EA, Dueck AC, McCullough AE, et al (2103). Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol, 31, 2115-22.
  22. Perez-Tenorio G, Alkhori L, Olsson B, et al (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res, 13, 3577-84. https://doi.org/10.1158/1078-0432.CCR-06-1609
  23. Perren A, Weng LP, Boag AH, et al (1999). Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol, 155, 1253-60. https://doi.org/10.1016/S0002-9440(10)65227-3
  24. Prat A, Baselga J (2013). Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. J Clin Oncol, 31, 1703-6. https://doi.org/10.1200/JCO.2012.48.4998
  25. Razis E, Bobos M, Kotoula V, et al (2011). Evaluation of the association of PI3KCA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat, 128, 447-56. https://doi.org/10.1007/s10549-011-1572-5
  26. Ross JS, Slodkowska EA, Symmans WF, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-68. https://doi.org/10.1634/theoncologist.2008-0230
  27. Saal LH, Holm K, Maurer M, et al (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 65, 2554-9. https://doi.org/10.1158/0008-5472-CAN-04-3913
  28. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
  29. Song CH, Park SY, Eom KY, et al (2010). Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res, 12, 20.
  30. Spataro VJ, Litman H, Viale G, et al (2003). Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer, 97, 1591-600. https://doi.org/10.1002/cncr.11224
  31. Spector NL, Blackwell KL (2009). Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 27, 5838-47. https://doi.org/10.1200/JCO.2009.22.1507
  32. Tsutsui S, Inoue H, Yasuda K, et al (2005). Inactivation of PTEN is associated with a low p27Kip1 protein expression in breast carcinoma. Cancer, 104, 2048-53. https://doi.org/10.1002/cncr.21471
  33. Wilken JA, Maihle NJ (2010). Primary trastuzumab resistance: new tricks for an old drug. Ann Y D Acad Sci, 1210, 53-65. https://doi.org/10.1111/j.1749-6632.2010.05782.x
  34. Yakes FM, Chinratanalab W, Ritter CA, et al (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res, 62, 4132-41.
  35. Yonemori K, Tsuta K, Shimizu C, et al (2009). Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol, 26, 344-9. https://doi.org/10.1007/s12032-008-9127-2

Cited by

  1. PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer vol.12, pp.3, 2017, https://doi.org/10.1371/journal.pone.0172911
  2. Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317695529
  3. Protein Kinase Targets in Breast Cancer vol.18, pp.12, 2017, https://doi.org/10.3390/ijms18122543
  4. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer vol.21, pp.3, 2018, https://doi.org/10.1080/13685538.2018.1424130
  5. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma vol.36, pp.1, 2019, https://doi.org/10.1007/s12032-018-1234-0